Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | FADS1 | O60427 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1800338 | 0.91 | KMT2A (0.38) | SCDPTGS2FADS1HCRTR1HCRTR2 | |
| SCHEMBL12358862 | 0.86 | HCRTR1 (0.41) | HTR2BROCK2HCRTR1HCRTR2 | |
| SCHEMBL1797369 | 0.84 | TRPV1 (0.43) | SCDPTGS2FADS1 | |
| SCHEMBL1795354 | 0.84 | TRPV1 (0.36) | SCDPTGS2NPBWR1FADS1HTR2B | |
| SCHEMBL12359252 | 0.84 | KDM1A (0.39) | HTR2BROCK2HCRTR1HCRTR2 | |
| SCHEMBL1799054 | 0.84 | TRPV1 (0.41) | SCDFADS1HTR2B | |
| SCHEMBL1798578 | 0.83 | KDM1A (0.50) | — | |
| SCHEMBL12358842 | 0.81 | SCD (0.56) | SCDNPBWR1FADS1 | |
| SCHEMBL1794849 | 0.80 | KDM1A (0.40) | SCDFADS1 | |
| SCHEMBL1796271 | 0.79 | BRD4 (0.41) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190344-A1 | BENZIMIDAZOLE MODULATORS OF VR1 | VRK1, VRK2, VIL1 | SCD 4754/4885PTGS2 1242/4885NPBWR1 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.